Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 3 of 3 results for ta455

  1. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.

    Technology appraisal guidance
    Published
    12 July 2017
    View recommendations

    Sections for TA455

  2. Trials that evaluate utility values (using generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility analyses.

    Recommendation ID TA455/1 Question Trials that evaluate utility values (using generic preference-based measures) in children and young

    Research recommendation
    Published
    15 October 2018

  3. Research recommendations

    TA455/1 | Trials that evaluate utility values (using generic preference-based measures)